Knight Therapeutics Inc. Announces Board Change
(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 01/21/15 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight''s Board of Directors. "Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date," said Jonathan Ross Goodman, President and CEO of Knight. "In his place, we welcome Ed Schutter, founder and CEO of US specialty pharmaceutical Arbor Pharmaceuticals, LLC., to our leadership team. Ed is a proven pharmaceutical entrepreneur."
About Ed Schutter
Ed Schutter is President and CEO of Arbor Pharmaceuticals, LLC. ("Arbor"). Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which was sold to Shionogi & Co. Ltd. in 2008 for $1.4 billion. Prior to Sciele, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. Ed was also a co-founder of North Hampton Pharmaceuticals which later changed its name to Ventrus Biosciences, a Nasdaq listed company. In addition to his board duties with Arbor, Ed is on the Board of Trustees for Mercer University, is the Chairman of the Board of Georgia Bio, is a member of the Emory University New Venture Advisory Board, and a founding member and Executive Director of the Atlanta based Bio/Med Investor Network Inc. Ed holds a Bachelor degree in Pharmaceutical Sciences from Mercer University, a Masters of Business Administration from Kennesaw State University and has also completed post graduate work in international business at Nyenrode University in the Netherlands.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight''s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company''s web site at or .
Forward Looking Statements
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company''s Listing Application dated February 21, 2014 and its short form prospectus dated December 16, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-4831
514-481-4116 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.01.2015 - 16:00 Uhr
Sprache: Deutsch
News-ID 1331813
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONTREAL, CANADA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Knight Therapeutics Inc. Announces Board Change
"
steht unter der journalistisch-redaktionellen Verantwortung von
Knight Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
